Pregabalin Capsule
Product Images NDC 72162-1545

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image Description (Lbl721621545)

Label for Pregabalin Capsules 150 mg, oral dosage form, Rx only. The label shows the NDC 72162-1545-9 and indicates a package size of 90 capsules. It includes the Bryant Ranch Prepack logo and states repackaging by Bryant Ranch Prepack, Inc., Burbank, CA, and manufacturing by ScieGen Pharmaceuticals Inc. Storage instructions specify room temperature (20°-25°C).*

FDA Label Image

Figure 1 (Pregabalin Fig01)

A line graph showing the percentage of patients improved on the vertical axis against the percent improvement in pain from baseline on the horizontal axis. The graph compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo.*

FDA Label Image

Figure 2 (Pregabalin Fig02)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline. It shows two curves labeled Pregabalin 100 mg three times a day and Placebo, indicating patient responses across different pain improvement percentages.*

FDA Label Image

Figure 3 (Pregabalin Fig03)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline, comparing Pregabalin at 75 mg, 150 mg, 300 mg taken twice a day, and placebo. The x-axis shows percent improvement in pain, and the y-axis shows percent of patients improved.*

FDA Label Image

Figure 4 (Pregabalin Fig04)

A line graph comparing percent improvement in pain from baseline versus percent of patients improved for Pregabalin 200 mg three times daily, Pregabalin 100 mg three times daily, and placebo groups. The vertical axis shows percent of patients improved, and the horizontal axis shows percent improvement in pain from baseline, with data curves for each treatment group.*

FDA Label Image

Figure 5 (Pregabalin Fig05)

A line graph comparing the percent of patients improved versus percent improvement in pain from baseline for three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph shows trends of patient improvement across increasing pain relief percentages.*

FDA Label Image

Figure 6 (Pregabalin Fig06)

A bar graph comparing responder rates (%) by treatment groups in two studies labeled Study E1 and Study E3. The x-axis shows different dosages of the drug and placebo, with sample sizes below. The y-axis indicates responder rate percentage from 0% to 60%. Study E1 includes placebo and four dosing groups (50 mg/day, 150 mg/day, 300 mg/day, 600 mg/day). Study E3 includes placebo and two dosing groups (300 mg/day, 600 mg/day). Some bars are marked as statistically significant versus placebo.*

FDA Label Image

Figure 7 (Pregabalin Fig07)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day. The graph includes data points for four studies labeled E1 BD, E2 TID, E3 BD, and E3 TID, with significant p-values indicated. The x-axis represents dose from 0 to 600 mg/day, the y-axis shows seizure reduction from 0 to 60 percent. The graph notes that 0 dose represents placebo and only significant p-values are shown.*

FDA Label Image

Figure 9 (Pregabalin Fig08)

A line graph depicting the percent improvement in pain from baseline on the x-axis and the percent of patients improved on the y-axis. The graph compares Pregabalin daily doses of 300 mg, 450 mg, and 800 mg with placebo, showing the relationship between dose levels and pain improvement percentages in patients.*

FDA Label Image

Figure 10 (Pregabalin Fig09)

A Kaplan-Meier survival curve graph comparing Pregabalin and placebo groups over 180 days. The y-axis shows the estimated percentage of subjects without LTR, and the x-axis represents days. The solid line depicts Pregabalin, with higher survival percentages compared to the dashed line for placebo.*

FDA Label Image

Figure 11 (Pregabalin Fig10)

A line graph comparing percentage of subjects improved over varying levels of percent improvement from baseline to week 12 BOCF, for Pregabalin versus Placebo. The x-axis shows percent improvement intervals from >0 to 100, and the y-axis shows the percentage of subjects improved from 0 to 100. The Pregabalin line shows consistently higher percentages of subjects improved across improvement intervals than the Placebo line.*

FDA Label Image

Figure 12 (Pregabalin Fig11)

A line chart comparing the percentage of subjects improved from baseline to week 16 for Pregabalin versus placebo. The horizontal axis shows percent improvement from 0 to 100, while the vertical axis presents percent of subjects improved, from 0 to 100. Pregabalin is represented by a solid line, showing higher improvement percentages than placebo shown by a dashed line.*

FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

A formula for calculating creatinine clearance (CLcr) based on age, weight, and serum creatinine, with an adjustment factor for female patients. This equation is commonly used in pharmacokinetics and dosing considerations.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of Pregabalin, showing its molecular arrangement with key functional groups including an amino group (NH2) and a carboxylic acid group (CO2H).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.